Suvemcitug injection, trifluridine/tipiracil tablets — Competitive Intelligence Brief

Suvemcitug injection, trifluridine/tipiracil tablets (Suvemcitug injection, trifluridine/tipiracil tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog; antimetabolite. Area: Oncology.

phase 3 Nucleoside analog; antimetabolite Thymidylate synthase; DNA Oncology Small molecule

Target snapshot

Suvemcitug injection, trifluridine/tipiracil tablets (Suvemcitug injection, trifluridine/tipiracil tablets) — Jiangsu Simcere Pharmaceutical Co., Ltd.. Trifluridine/tipiracil is a nucleoside analog combination that inhibits thymidylate synthase and incorporates into DNA to induce apoptosis in cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Suvemcitug injection, trifluridine/tipiracil tablets TARGET	Suvemcitug injection, trifluridine/tipiracil tablets	Jiangsu Simcere Pharmaceutical Co., Ltd.	phase 3	Nucleoside analog; antimetabolite	Thymidylate synthase; DNA
TS-1, oxaliplatin	TS-1, oxaliplatin	Samsung Medical Center	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase; DNA (platinum crosslinking)
Fluoropyrimidine-based Chemotherapy	Fluoropyrimidine-based Chemotherapy	Hoffmann-La Roche	phase 3	Antimetabolite chemotherapy	Thymidylate synthase; DNA/RNA incorporation
CAPEOX/Capecitabine	CAPEOX/Capecitabine	Qilu Pharmaceutical Co., Ltd.	phase 3	Antimetabolite; Fluoropyrimidine	Thymidylate synthase; DNA/RNA synthesis
Trifluridine cures	Trifluridine cures	Centre Hospitalier Universitaire Dijon	phase 3	Nucleoside analog; antimetabolite	Thymidylate synthase; DNA
Carac® (Fluorouracil) Cream	Carac® (Fluorouracil) Cream	Actavis Inc.	phase 3	Antimetabolite; Pyrimidine analog	Thymidylate synthase; DNA and RNA synthesis
Pifeltro	DORAVIRINE	Merck & Co.	marketed	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]		2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog; antimetabolite class)

1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
2. Astellas Pharma Global Development, Inc. · 1 drug in this class
3. AstraZeneca · 1 drug in this class
4. Celgene · 1 drug in this class
5. Centre Hospitalier Universitaire Dijon · 1 drug in this class
6. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
7. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Eisai Inc. · 1 drug in this class
9. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
10. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class